Stocks · News reference
IceCure Medical Highlights Peer‑Reviewed Publications Reinforcing Cryoablation’s Growing Clinical Role In Breast Cancer Treatment De‑Escalation, Including FDA Authorization Of ProSense, Updated ASBrS Guidelines, And Positive ICE3 5‑Yr Outcomes
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 1:14 PM
- Checked
- Aug 13, 2026, 1:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
IceCure Medical Says JHM-IRB Of West Cancer Center & Research Institute In Germantown, Tennessee, Approves Post-Marketing Study For ProSense Cryoablation In Local Treatment Of Low-Risk Breast Cancer
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TNCAESAREA, Israel,
Read original at benzingaIcecure Medical Q2 EPS $(1.37) Beats $(1.40) Estimate, Sales $889.000K Miss $1.450M Estimate
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.40) by 2.14 percent. This is a 23.89 percent increase over losses of $(1.80) per share from
Read original at benzinga